Abstract 1958P
Background
HN-STS is a challenging disease due to its diverse clinical presentation. In an attempt to refine the prognostication of these pts, the AJCC in its 8th edition proposed a new dedicated T staging group based on cutoffs of 2 and 4 cm for classifying T1, T2 and T3, and surrounding tissue invasion as T4, as opposed to the dichotomic T1-T2 5cm cutoff adopted by the 7th AJCC.
Methods
This is a retrospective study of pts diagnosed with nonmetastatic HN-STS treated with curative intent in a single tertiary hospital, approved by the institutional ethical review committee. The aim was to compare the 8th AJCC T staging to the previous classification as a prognostic tool for HN-STS, added to other variables such as age, histological subtype, grade and regional lymph node metastasis (LNM). AJCC 7th and 8th have been compared regarding T staging with Cohen’s kappa coefficient (KC) using inter-rater agreement analysis. The Kaplan-Meier estimator was used to calculate median survival time and differences in time-to-event outcomes were assessed using the log-rank test. Cox proportional hazard model was used to assess the effect of features in overall survival (OS).
Results
From 1997 to 2000, 135 pts were identified in institutional archives. Sarcoma NOS (N=50) and Leiomyosarcoma (N=17) were the most common histologic subtypes, as well as high-grade tumors (N=85). KC of inter-rater agreement was 0.46, statistically significant (p=0.03), indicating poor agreement between both T staging systems. Regarding OS, AJCC 7th (T1 and T2) and 8th (T1, T2, T3 and T4) T size stratification was not statistically different (P=0.42 and P=0.27, respectively). High-grade (71.4% vs 93.6%, P=0.005) and regional LNM (31.3% vs 81.4%, P=0.008) had worse 5-year OS in Cox multivariate analysis. Pts with tumor size>4cm or local invasion, high grade and LNM had 2.30, 7.11 and 4.37-fold increased risk of death respectively.
Conclusions
In our series, neither 7th nor 8th AJCC T size classifications adequately stratified prognostic groups or correlated survival for HN-STS pts. The 8th AJCC T4, the high-grade tumors and regional LNM demonstrated significant worse prognostic impact in pts harboring HN-STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1820P - Cardiovascular effects of androgen receptor signalling inhibitors in the treatment of advanced and metastatic prostate cancer: A systematic review and meta-analysis of randomised controlled trials
Presenter: Omar El-Taji
Session: Poster session 15
1821P - High serum FSH/T ratio as a marker for the development of cardiovascular disease in ADT recipients
Presenter: Jehonathan Pinthus
Session: Poster session 15
1822P - PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT
Presenter: Michael Sun
Session: Poster session 15
1823P - The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients
Presenter: Dianne Bosch
Session: Poster session 15
1824P - Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer
Presenter: Vivek Narayan
Session: Poster session 15
1825P - Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Presenter: David Goode
Session: Poster session 15
1826P - Lutetium-177-PSMA in pre- and post-taxane mCRPC setting: Results from a phase II clinical trial
Presenter: Emilio Giunta
Session: Poster session 15
1827P - Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel George
Session: Poster session 15
1828P - ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)
Presenter: Scott Tagawa
Session: Poster session 15
1829P - Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15